BaroPace Reports the First Patient Enrolment of PressurePace in (RelieveHFpEF-II) Trial for Non-Pharmacologic Hypertension and Heart Failure
- The first patient has been enrolled in FIH clinical trial (RelieveHFpEF-II) evaluating PressurePace, the real-time closed-loop pacemaker control algorithm that regulates a cardiac pacemaker in patients with HFpEF. The study was conducted in India
- The 1EPs of the trial are safety, improved exercise performance (modified BRUCE treadmill protocol & six-minute walk test), and the Minnesota Living with Heart Failure Questionnaire while the 2EPs incl. blood pressure control (systolic & diastolic blood pressure and 24hr. blood pressure monitoring), atrial fibrillation incidences, and hospitalization frequency
- Patients maintaining stable blood pressure & body weight are randomized to 3wks. of standard pacemaker therapy over PressurePace after 1wk. of baseline measurements
Ref: Businesswire | Image: BaroPace
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.